• ๐ŸŒŽ Worldwide
    • ๐Ÿ‡บ๐Ÿ‡ธ U.S.
    • ๐Ÿ‡จ๐Ÿ‡ฆ Canada
    • ๐Ÿ‡ฌ๐Ÿ‡ง United Kingdom
    • ๐ŸŒ Asia
    • ๐ŸŒ Europe
    • ๐ŸŒŽ Latin America
    • ๐ŸŒ Oceania and Australasia
The Daily Marijuana Observer
SUBSCRIBE
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
No Result
View All Result
Home Investments

Tetra Bio-Pharma and Ovensa Will Engage in a Collaboration to Tackle Brain Cancer

by Globe Newswire
April 11, 2019
in Investments, Marijuana Stocks, Press Releases
WeedMD Subsidiary Starseed Medicinal Signs Innovative Benefits Provider myHSA to Medical Cannabis Program

Photo by EVG photos on Pexels.com

48
SHARES
ShareShare

OTTAWA, April 11, 2019 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or theย “Company”) (TSX-V: TBP) (OTCQB: TBPMF), today announced that it has entered into a collaboration agreement with Ovensa Inc. (“Ovensa”) to evaluate TRIOZANโ„ข, a proprietary nanomedicine platform for targeted delivery of cannabinoids to brain tumor cells.

“Glioblastoma multiforme (GBM) is a common and fatal type of brain cancer and sadly took the lives of Senator John McCain and singer Gordon Downey. Our collaboration with Ovensa will evaluate if TRIOZANร” allows a targeted delivery of cannabinoids to the brain tumor.ย  There is some published evidence demonstrating the activity of cannabinoids on brain tumors.ย  If successful this could provide an increased efficacy when this treatment is used as an adjunct to radiotherapy and or chemotherapy. This technology is also being investigated for the delivery of an antibody to the brain as part of a collaboration between Ovensa and Takeda Pharmaceutical. Our collaboration with Ovensa is part of our ongoing cancer research program,โ€ said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma.

โ€˜โ€™Ovensaโ€™s TRIOZANTMย Delivery Platform allows a high engineering flexibility where personalized nanomedicines are designed according to various parameters such as pathology, gene and molecular profile, cell targeting, type of payload, route of administration and multi-combination. The current collaboration is aimed at engineering a targeted Glioblastoma Dual-Cannabinoid TRIOZANTM-based therapeutic to achieve synergistic effects with therapeutic tools such as chemotherapy, radiotherapy and immunotherapyโ€, said Ovensa’s President and CEO, Mr. Stรฉphane Gagnรฉ.

About Glioblastoma Multiforme (Brain Cancer)
Glioblastoma multiforme (GBM) is the most common and most malignant of the glial tumors with a 5-year survival rate lower than 5%. Its incidence in most European and North American countries is approximately 2-3 new cases per 100,000 people per year. The tremendous unmet need in GBM is substantiated by the lack of treatment progress and improvement in overall survival in this indication over the last several years.

About Ovensa Inc
Ovensa is a preclinical stage company fighting inherent therapeutic resistance in complex diseases by generating advanced nanotherapeutics using its proprietary TRIOZANโ„ข Delivery Platform. The company focuses on advancing its lead drug candidates as well as generating novel nanotherapeutic candidates in collaboration with pharmaceutical companies for applications in CNS and immuno-oncology. For more information visit:ย www.ovensa.com

Aboutย Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit:ย www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of CAUMZ and its other drug candidates, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Share this:

  • Click to email this to a friend (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)
Tags: OTC:TCPMFOvensa Inc.Tetra Bio-Pharma Inc.TRIOZANTSXV:TBP

Get Real-Time Updates from MJobserver.com

Unsubscribe

Globe Newswire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Related Posts

Marinol Dronabinol THC Pharmaceutical
Events

30+ Expert Speakers to Present at the 3rd Annual Cannabinoid-Derived Pharmaceuticals Summit

July 9, 2020
Cannabis Stocks on the Rise Today
Trading

5 of Todayโ€™s Biggest Cannabis Stock Gainers on Thursday, June 4, 2020

June 4, 2020
storz & bickel cannabis vaporizer
Press Releases

Tetra Bio-Pharma and Storz & Bickel Enter into Commercial Sales Agreement for the Mighty Medic Vaporizer

June 4, 2020
Submitting a Comment to the FDA on CBD in Foods and Beverages
Health

Tetra Receives its 4th FDA Orphan Drug Designation

April 16, 2020
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Investments

Tetra Biopharma Survey Validates Primary Endpoint of SERENITYยฉ Clinical Trial

March 26, 2020
Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs
Canada

Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs

February 20, 2020
Load More
Next Post
Jushi Announces the Beginning of Adult-Use Cannabis Sales at its Sauget, Illinois Dispensary

Cresco Labs Continues Its Illinois Expansion with Regulatory Approval for Three Dispensaries

Comments 1

  1. Pingback: PRO: Paradigm Capital Sees 150% Upside for Shares of Tetra Bio-Pharma

Leave a Comment! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

๐Ÿšจ Subscribe to Stock Alerts

Get Live Updates on Breaking News

Subscribe Now

โœ‰๏ธ Subscribe to Our Newsletter!

* indicates required

๐Ÿ”Ž Search Marijuana Stocks

๐Ÿ“ฐ Recent News

  • Verano Holdings Enters into Agreement to Expand Arizona Footprint
  • Green Thumb Industries Announces Initial Public Offering in the U.S. to Raise US$100,000,000
  • Greenlane Announces Dismissal of Remaining Securities Class Action
  • Indiva Reports Record Market Share for January 2021
  • Acreage Announces Fourth Quarter And Full Year 2020 Earnings Date
Facebook Twitter Instagram LinkedIn Youtube

Cannabis News by Region

  • ๐Ÿ‡บ๐Ÿ‡ธ United States
  • ๐Ÿ‡จ๐Ÿ‡ฆ Canada
  • ๐Ÿ‡ฌ๐Ÿ‡ง United Kingdom
  • ๐ŸŒ Asia
  • ๐ŸŒ Europe
  • ๐ŸŒŽ Latin America
  • ๐ŸŒ Oceania and Australasia

Cannabis Tools & Resources

  • ๐Ÿ“… Calendar
  • ๐Ÿ“Š Databases
  • ๐Ÿ“‡ Directories
  • ๐Ÿ”” RSS Feeds
  • ๐Ÿ“บ Videos

Find Cannabis Business Services

  • โš–๏ธ Attorneys & Law Firms
  • ๐Ÿ“Š Accountants & Accounting Firms
  • ๐Ÿ’ก Consultants & Consulting Firms
  • ๐Ÿ“ฒ Marketing Agencies & Firms

The Daily Marijuana Observer

  • Subscribe
  • About MJobserver.com
  • Affiliate Marketing Disclosure
  • Legal Disclaimer
  • Privacy Policy
  • Contact Us

Advertise with Us

  • ๐Ÿ‘€ Advertise
  • ๐Ÿ“ฃ DMO Newswire
  • ๐Ÿ“‡ List in Our Databases

ยฉ 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observerโ„ข (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

No Result
View All Result
  • Home
  • Latest
  • ๐Ÿ”’ PRO
    • ๐Ÿ”’ A.M. Watchlist
    • ๐Ÿ”’ Analyst Action
  • ๐Ÿ’ผ Business
  • ๐Ÿ“ˆ Investments
    • ๐Ÿ“ˆ Stocks
    • ๐Ÿ’ฐ ETFs and Funds
    • ๐Ÿ’ญ Market Commentary
    • ๐Ÿ“ฐ Press Releases
    • ๐Ÿ“… Earnings Calendar
  • โš–๏ธ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • ๐Ÿ‘ฅ People
    • โšฝ Athletes
    • ๐Ÿ’ผ Executives
    • ๐ŸŒŸ Celebrities
    • ๐Ÿ›’ Consumers
    • โš•๏ธ Doctors
    • ๐Ÿ’Š Patients
  • ๐Ÿ’Š Health
  • ๐Ÿ“‡ Databases
    • ๐Ÿ“ˆ Stock Databases
    • ๐Ÿ’ฐ Fund Databases
    • ๐Ÿ’ผ Service Providers Databases
    • ๐Ÿฆ Marijuana Stock Brokers
    • ๐Ÿ’ฒ Marijuana Cryptocurrencies

ยฉ 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observerโ„ข (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.